Montag & Associates’s Alnylam Pharmaceuticals ALNY Stock Holding History

Montag & Associates’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.54K	Hold	5	–	–	﹤0.01%	864
2025 Q4	$1.86K	Sell	5 -1	-17%	-$443	﹤0.01%	873
2025 Q3	$2.73K	Hold	6	–	–	﹤0.01%	882
2025 Q2	$1.9K	Hold	6	–	–	﹤0.01%	852
2025 Q1	$1.57K	Hold	6	–	–	﹤0.01%	913
2024 Q4	$1.37K	Buy	6 +1	+20%	+$263	﹤0.01%	918
2024 Q3	$1.35K	Hold	5	–	–	﹤0.01%	946
2024 Q2	$1.19K	Hold	5	–	–	﹤0.01%	915
2024 Q1	$733	Sell	5 -2	-29%	-$334	﹤0.01%	949
2023 Q4	$1.34K	Hold	7	–	–	﹤0.01%	874
2023 Q3	$1.24K	Hold	7	–	–	﹤0.01%	862
2023 Q2	$1.33K	Hold	7	–	–	﹤0.01%	878
2023 Q1	$1.4K	Hold	7	–	–	﹤0.01%	876
2022 Q4	$1.66K	Buy	+7	New	+$1.49K	﹤0.01%	876

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Montag & Associates's ALNY Position: Q1 2026 in Review

Montag & Associates held its Alnylam Pharmaceuticals (ALNY) position steady in Q1 2026 at 5 shares worth $1.54K. The position accounts for ﹤0.01% of the portfolio, ranked #864.

Montag & Associates first reported a position in ALNY in Q4 2022 and has held it in 14 quarters since. The position peaked at $2.73K in Q3 2025. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

Montag & Associates held 5 shares of Alnylam Pharmaceuticals worth $1.54K as of Q1 2026.
Montag & Associates left its Alnylam Pharmaceuticals share count unchanged in Q1 2026.
Alnylam Pharmaceuticals made up ﹤0.01% of Montag & Associates's portfolio in Q1 2026, its #864 holding.
Montag & Associates first reported a position in Alnylam Pharmaceuticals in Q4 2022 and has held it in 14 quarters since.
Montag & Associates's Alnylam Pharmaceuticals position peaked at $2.73K in Q3 2025.
786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Montag & Associates's 13F filing for Q1 2026, filed 29 Apr 2026.